FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

NCT03723967 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Durvalumab with Carboplatin/Paclitaxel

Sponsor

Centre Leon Berard